NR4A1 and breast neoplasm: Indeed, while the IRSN-23 study did not select patients according to hormone receptor status, results showed that the Gp-NR group was significantly enriched for luminal breast tumours (p < 0.005), which would typically show less response to chemotherapy [76,77].